Acellular Dermal Allograft for Chronic Diabetic Wounds
A legfontosabb adatok
- Ki végzi
- University Health Network, Toronto
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2024. ápr. 1.
- Várható befejezés
- 2026. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- decellularized dermal matrix
- A regiszteradat frissítve
- 2024. január 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a diabetic foot ulcer that is healing slowly. They will be treated with DermGEN™, a skin graft made from donated human skin.
- Életkor
- 18 Years and older
- Nem
- All
- A betegség stádiuma
- A diabetic foot ulcer present for at least 2 weeks, which healed less than 30% in the 2 weeks before Day 0. It is at least 1 cm2 in size. It goes through the skin into the tissue below, but muscle, tendon, bone or joint capsule are not exposed. It has no dead tissue or infection and is fit to receive a skin graft. Blood flow to the foot must be good enough, measured by toe pressure.
- Korábbi kezelés
- People cannot join if they take corticosteroids by mouth or injection, immune-suppressing drugs or cytotoxic drugs, or are expected to need them during the study.
A részvétel fő kizáró okai
- Gangrene (dead tissue) on the affected foot
- Ulcer over a Charcot deformity (fractures or dislocation)
- Ulcer not caused by diabetes
- Pregnancy at the start of or during the study
- Taking corticosteroids, immune-suppressing drugs or cytotoxic drugs
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- A subject will be considered eligible to participate in this study if each of the following inclusion criteria is satisfied:
- Patient's ulcer has been present for a minimum of 2 weeks as of Day 0
- Study ulcer has healed <30% in size during the 2 weeks prior to Day 0
- Ulcer area is ≥1 cm2 prior to debridement at Day 0 of study
- Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule
- Ulcer is free of necrotic debris and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0
- Patient has adequate circulation to the foot as evidenced by toe pressure measurement
- Female patients are not pregnant at time of, or during study
- Patient and caregiver ready and willing to participate and comply with follow-up regime
- Patient or legal representative has read and signed the Institutional Ethics Review Board approved informed consent form
Ki nem vehet részt
- Patient receiving oral or parenteral corticosteroids, immunosuppression or cytotoxic agents, or is anticipated to require such agents during study
- Ulcer is over Charcot deformity (fractures or dislocation)
- Ulcer is non-diabetic in etiology
- A subject will not be considered eligible to participate in this study if any one of the following exclusion criteria is satisfied:
- Evidence of gangrene on affected foot
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to determine the efficacy of a novel decellularized dermal matrix (DDM) DermGEN™ for the treatment of diabetic foot ulcers (DFU). Despite several advances in wound treatments, hard-to-heal wounds, such as diabetic foot ulcer, still require 12 to 16 weeks to achieve complete closure. Although the focus of most research into wound-healing treatments has been on moisture and bacterial control, new approaches that target the instability of the extracellular matrix (ECM) in a wound are timely and much needed, particularly for hard-to-heal wounds such as DFUs. Innovative technologies that provide ECM interactions halt the chronic inflammatory cycle and stimulate cells that allow for tissue regeneration and wound healing. DermGEN™ is a human dermal allograft that has been minimally processed from human skin to remove epidermal and dermal cells while preserving the structure and intrinsic properties of the natural extracellular matrix of the dermis. This has potential to facilitate a shorter wound-healing time.
A vizsgálat csoportja
- DermgenA vizsgált kezelés
Application of Dermgen
Kezelés: decellularized dermal matrix
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2024. január 29.